期刊文献+

托吡酯对癫癎大鼠海马神经元凋亡的保护作用 被引量:1

Protective effect of topiramate on neuronal apoptosis in hippocampus of rats with seizure
下载PDF
导出
摘要 目的探讨托吡酯(TPM)对癫疒间发作大鼠海马神经元凋亡的保护作用。方法给予戊四氮(PTZ)致疒间大鼠TPM 80 mg/(kg.d)(大剂量TPM组)、40 mg/(kg.d)(中剂量TPM组)和生理盐水(对照组)灌胃,共14 d。用原位末端标记(TUNEL)方法标记DNA片段,原位检测大鼠海马CA1和CA3区的凋亡神经元。结果各组大鼠海马CA1、CA3区均出现TUNEL阳性细胞。对照组海马CA1、CA3区TUNEL阳性细胞数分别为(35.83±4.58)个和(36.83±3.87)个;中剂量TPM组分别为(31.52±3.43)个和(32.35±4.69)个;大剂量TPM组分别为(23.50±2.81)个和(25.50±3.72)个。大剂量TPM组与对照组比较差异有非常显著性(均P<0.001),与中剂量TPM组比较差异有显著性(均P<0.05);中剂量TPM组与对照组相比差异无显著性(均P>0.05)。结论大剂量TPM对癫疒间发作后的神经元损伤具有一定的保护作用。 Objective To investigate the protective effect of topiramate (TPM) on neuronal apoptosis in rats with acute seizures. Methods We treated the PTZ-induced seizure rats with TPM at 80mg/( kg·d) (high-dose group) and 40mg/( kg·d) ( middle-dose group) or physiological saline ( control group) for 2 weeks. Neuronal apoptosis in CA1 and CA3 regions in hippoeampus was identified by terminal deoxynucletidyl transferase-mediated dUTP-biotin in situ nick end labeling (TUNEL) assay. Results Two weeks following seizures, TUNEL-positive neurons were detected in CA1 and CA3 regions each group. The numbers of TUNEL-positive neurons in CA1 and CA3 of control group were 35.83 ± 4. 58 and 36.83 ±3.83, 23.50 ± 2. gl and 25.50 ±3.72 of high-dose TPM group, 31.52 ±3.43 and 32.35 ± 4. 69 of middle-dose TPM group. There was a very significant difference between highdose TPM group and control group (all P 〈 0. 001 ) , and a significant difference between high-dose TPM group and middle-dose group(all P 〈 0. 05). However, then was no obvious difference between middle-dose TPM group and control group (all P 〉 0.05 ). Conclusion High dose administration of TPM after experimental status epilepticus may attenuate seizure-induced hippocampal neuronal injury.
出处 《临床神经病学杂志》 CAS 北大核心 2005年第5期367-369,共3页 Journal of Clinical Neurology
关键词 癫痫 凋亡 托吡酯 epilepsy apoptosis topiramate
  • 相关文献

参考文献15

二级参考文献33

  • 1Easterling DE, Zakszewski T, Moter MD, et al. Plasma pharmacokinetics of topiramate,a new anticonvulsant in humans. Epilepsia,1988,29: 662 被引量:1
  • 2Faught E,Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-renging trial in refractory partial epilepsy using 200-,400-,and 1000-mg daily dosage. Neurology, 1996, 46:1684 被引量:1
  • 3Brodie MJ, Biton V, Montouis GD, et al. Topiramate therapy in patients with generalized tonic-clonic seizures with or without focal onset: Long-term outcome. Epilepsia, 1998,39(Suppl. 2): 2 被引量:1
  • 4Ritter FJ, Glauser TA, Sachdeno RC, et al. Long-term experince with topiramate in Lennox- Gastaut syndrome. Epilepsia, 1998,39(Suppl. 2): 2 被引量:1
  • 5Glauser TA, Elterman R, Wyllic E, et al. Open-label topiramate in pediatric partial epilepsy. Epilepsia, 1997, 38(Suppl. 3):94 被引量:1
  • 6Ben-menachem E. Exp. Opin. Invest. Durgs, 1997,6: 1085 被引量:1
  • 7Sachdeo RC, Sachdeo SK,Walker SA,et al.Steadystate pharmacokinetics of topiramate and carbamazepine in papients with epilepsy during monotherapy and concommitant therapy. Epilepsia, 1996,37: 774 被引量:1
  • 8Rosenfeld WE, Liao S, Kramer LD,et al.Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concommitant therapy. Epilepsia, 1997, 38:324 被引量:1
  • 9Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia, 1996, 37(Suppl.2):S 18 被引量:1
  • 10Reife RA, Lim P, Pledger G. Topiramate: side-effect profile in double-blind studies.Epilepsia, 1995, 36(Suppl.4): 34 被引量:1

共引文献28

同被引文献10

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部